Dossier assessment
Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Report documents
-
Dossier assessment
Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Additional information
Federal Joint Committee (G-BA)
2019-05-02 A G-BA decision was published.
Project details
- Project no.
- G18-18
- Commission
- Commission awarded on 01.11.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
In accordance with § 35a (para. 1, sentence 11) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Axicabtagene ciloleucel report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.
Connected Projects
-
Dossier assessment
Axicabtagene ciloleucel (B-cell lymphoma PMBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Axicabtagene ciloleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Axicabtagene ciloleucel (follicular lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Withdrawn commission
-
Dossier assessment
Axicabtagene ciloleucel (DLBCL and HGBL) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Withdrawn commission
-
Dossier assessment
Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed